Abstract
ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. Key words: Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have